Oncolytics Biotech(R) Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer.

Oncolytics Biotech has received regulatory clearance to begin a new study on pancreatic cancer. The study will evaluate the use of pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) and an anti-PD-L1 inhibitor in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). The study is supported by a Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN). The results from this study could potentially improve outcomes for patients with pancreatic cancer. [Extracted from the article]